Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
- PMID: 20385793
- DOI: 10.1182/blood-2009-11-254441
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Abstract
Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic abnormalities remains uncertain. We studied the outcomes of 5876 patients (16-59 years of age) who were classified into 54 cytogenetic subgroups and treated in the Medical Research Council trials. In multivariable analysis, t(15;17)(q22;q21), t(8;21)(q22;q22), and inv(16)(p13q22)/t(16;16)(p13;q22) were the only abnormalities found to predict a relatively favorable prognosis (P < .001). In patients with t(15;17) treated with extended all-trans retinoic acid and anthracycline-based chemotherapy, additional cytogenetic changes did not have an impact on prognosis. Similarly, additional abnormalities did not have a significant adverse effect in t(8;21) AML; whereas in patients with inv(16), the presence of additional changes, particularly +22, predicted a better outcome (P = .004). In multivariable analyses, various abnormalities predicted a significantly poorer outcome, namely abn(3q) (excluding t(3;5)(q25;q34)), inv(3)(q21q26)/t(3;3)(q21;q26), add(5q)/del(5q), -5, -7, add(7q)/del(7q), t(6;11)(q27;q23), t(10;11)(p11 approximately 13;q23), other t(11q23) (excluding t(9;11)(p21 approximately 22;q23) and t(11;19)(q23;p13)), t(9;22)(q34;q11), -17, and abn(17p). Patients lacking the aforementioned favorable or adverse aberrations but with 4 or more unrelated abnormalities also exhibited a significantly poorer prognosis (designated "complex" karyotype group). These data allow more reliable prediction of outcome for patients with rarer abnormalities and may facilitate the development of consensus in reporting of karyotypic information in clinical trials involving younger adults with AML. This study is registered at http://www.isrctn.org as ISRCTN55678797 and ISRCTN17161961.
Similar articles
-
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.Haematologica. 2014 May;99(5):821-9. doi: 10.3324/haematol.2013.096420. Epub 2014 Jan 24. Haematologica. 2014. PMID: 24463215 Free PMC article.
-
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.J Clin Oncol. 2010 Aug 20;28(24):3890-8. doi: 10.1200/JCO.2010.29.2771. Epub 2010 Jul 26. J Clin Oncol. 2010. PMID: 20660833
-
Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.J Clin Oncol. 2010 Jun 1;28(16):2674-81. doi: 10.1200/JCO.2009.24.8997. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439644
-
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review.
-
Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia.Clin Lab Med. 1990 Dec;10(4):755-67. Clin Lab Med. 1990. PMID: 2272173 Review.
Cited by
-
Detection of novel PPP1R1B::STARD3 fusion transcript in acute myeloid leukemia: a case report.J Med Case Rep. 2024 Jun 5;18(1):269. doi: 10.1186/s13256-024-04536-w. J Med Case Rep. 2024. PMID: 38835078 Free PMC article.
-
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.Blood Cancer J. 2024 May 31;14(1):91. doi: 10.1038/s41408-024-01069-9. Blood Cancer J. 2024. PMID: 38821940 Free PMC article.
-
Stellae-123 gene expression signature improved risk stratification in taiwanese acute myeloid leukemia patients.Sci Rep. 2024 May 14;14(1):11064. doi: 10.1038/s41598-024-61022-5. Sci Rep. 2024. PMID: 38744924 Free PMC article.
-
The RTK-RAS signaling pathway is enriched in patients with rare acute myeloid leukemia harboring t(16;21)(p11;q22)/FUS::ERG.Blood Sci. 2024 May 10;6(2):e00188. doi: 10.1097/BS9.0000000000000188. eCollection 2024 Apr. Blood Sci. 2024. PMID: 38742238 Free PMC article.
-
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis.Exp Hematol Oncol. 2024 May 10;13(1):49. doi: 10.1186/s40164-024-00514-6. Exp Hematol Oncol. 2024. PMID: 38730491 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous